Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients.
We studied the pharmacokinetics of amprenavir at doses of 600 mg twice a day or 1200 mg once a day, when co-administered to HIV-positive patients with 400 mg a day of atazanavir without a ritonavir booster. Our preliminary results suggest that amprenavir and atazanavir could be coadministered and that amprenavir could be boosted by atazanavir without the need for ritonavir pharmaco-enhancement.
Guffanti
Monica
M
Department of Infectious Diseases, Vita/Salute University, San Raffaele Scientific Institute, Milan, Italy.
De Pascalis
Cleta Raffaella
CR
Seminari
E
E
Fusetti
Giuliana
G
Gianotti
Nicola
N
Bassetti
Dante
D
Galli
Andrea
A
Castagna
Antonella
A
Lazzarin
Adriano
A
D000328:Adult; D000069446:Atazanavir Sulfate; D002219:Carbamates; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005663:Furans; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D006679:HIV Seropositivity / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000008:administration & dosage*; D010865:Pilot Projects; D011725:Pyridines / Q000008:administration & dosage*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D013449:Sulfonamides / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D016896:Treatment Outcome
D002219:Carbamates; D005663:Furans; D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D018894:Reverse Transcriptase Inhibitors; D013449:Sulfonamides; D000069446:Atazanavir Sulfate; C095108:amprenavir